THE US Food and Drug Administration has allowed the expanded use of Johnson & Johnson's drug, Tremfya, to treat adults with a type of chronic inflammatory bowel disease, the company said on Wednesday.

The Biden administration’s drug-price negotiation law threatens new product development and will lead to fewer new medicines ...

Johnson & Johnson already has a major presence in the crowded inflammatory bowel disease (IBD) space with its popular Stelara ...

Johnson & Johnson's latest effort to end tens of thousands of talc lawsuits has sparked a new legal battle between plaintiffs ...

The U.S. Food and Drug Administration has allowed the expanded use of Johnson & Johnson's drug, Tremfya, to treat adults with ...

Share on Facebook Share on Twitter If you missed it, late in the show yesterday the CMA nominations were announced. Morgan ...

Share on Facebook Share on Twitter Today, we salute Navy Veteran Jim Serger.  Jim has been on a mission to share the stories ...

Looking for a Halloween sweetheart? Use one of these Halloween pickup lines to create a scary-good connection.

If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate ...

magazine that despite his friends' disapproval, JJ has committed to supporting Katie through both the tough and good times.

If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the longstanding upfront discount model, the Health ...